巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Galecto

    GLTO
    2.020
    0.010
    0.50%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Galecto - 延遲價格・最後更新於 10/08 9:30
    最高位
    2.050
    最低位
    2.020
    開市價
    --
    前收市價
    2.010
    成交量(千)
    0.11
    成交額(百萬)
    0.00
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    51.30
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    4.680 - 1.170
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Galecto
    證券代碼
    GLTO.US
    所屬板塊
    Biotechnology
    公司業務
    Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
    發行量
    25261832
    公司總部
    Ole Maaloes Vej 3
    公司網址
    https://www.galecto.com
    公司電郵
    info@galecto.com
    公司電話
    +45 70705210
    暫無內容

    關於

    Galecto(GLTO.US)所屬的行業板塊為Biotechnology。
    Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
    詳細公司背景可參考: https://www.galecto.com